177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
Shilpa ThakurBrianna DaleyCorina MilloCraig CochranOrit JacobsonHuiyan LuZhantong WangDale O KiesewetterXiaoyuan ChenVasyl VaskoJoanna Klubo-GwiedzdzinskaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
A novel SST analogue, 177Lu-DOTA-EB-TATE, has the potential to be translated from bench to bedside for the targeted therapy of patients characterized by high uptake of SST analogues in metastatic lesions.